Vascular dementia

There are 976 papers on vascular dementia in aging research: 8 trials and 651 observational studies in people, 28 in animals, 1 in cells, 270 reviews. The newest story, Nov 10, 2026: “Diabetes drugs linked to lower death risk in vascular dementia”.

Disease

976 papers study it244 more mention it481 findings

37 new papers in 30 daysSee all 1,220 papers on vascular dementia

At a glance

Human cohorts link higher vascular dementia risk with frailty, higher biological age, hypertension and metabolic syndrome. Associations vary by context: weekend recovery sleep is linked with lower risk when weekday sleep is shorter than optimal, but higher risk when it is longer than optimal.

481 findings in 404 papers from 2002 to 2026, 106 of them since April 2026

“Persons with glaucoma had increased risks for AD (adjusted HR, 1.39; 95% confidence interval [CI], 1.35-1.43), VaD (1.66; 1.61-1.72), and all-cause dementia (1.57; 1.54-1.59).”
Risk of Alzheimer's Disease and Related Dementias in Persons with Glaucoma: A National Cohort StudyOphthalmology2023doi:10.1016/j.ophtha.2023.10.014
  • Human trial8
  • Humans651
  • Animals28
  • Cells1
  • In silico9

Interventions

31

GLP-1 receptor agonists

no changein humans2

2 studies
  1. GLP-1 receptor agonists were not clearly linked with vascular dementia in patients with CKD stage 3 or later and T2DM.

    “However, no significant differences were observed in vascular dementia, frontotemporal dementia, Parkinson's disease, extrapyramidal and movement disorders, or dementia with Lewy bodies.”

    Humansin patients with CKD stage 3 or later and T2DMranging from 90 days to 5 years

    GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

  2. GLP-1 receptor agonists were not clearly linked with vascular dementia in humans (compared with metformin as first-line monotherapy).

    “No significant difference was observed for VaD.”

    Humanscompared with metformin as first-line monotherapyn = 87,229

    Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes

    BMJ open diabetes research & care

More on GLP-1 receptor agonists

Migraine

no changein humans2RR 1.51

2 studies
  1. Migraine was not clearly linked with vascular dementia in humans.

    “Moreover, patients with migraine had a significantly higher incidence of Alzheimer's disease (adjusted HR = 1.31, 95% CI, 1.08-1.58), but not vascular dementia, than those without migraine.”

    Humans2002 to 2013

    Mid- and Late-Life Migraine Is Associated with an Increased Risk of All-Cause Dementia and Alzheimer's Disease, but Not Vascular Dementia: A Nationwide Retrospective Cohort Study

    Journal of personalized medicine

  2. Migraine was not clearly linked with vascular dementia in humans (RR: 1.51, 95% CI: 0.77-2.96).

    “we did not found any association between migraine and risk of vascular dementia (VaD) (RR: 1.51, 95% CI: 0.77-2.96)”

    Humansn = 249,303

    Meta-analysis of association between migraine and risk of dementia

    Acta neurologica Scandinavica

More on Migraine

Hormone replacement therapy

no changein humans1RR 0.86

1 study
  1. Hormone replacement therapy was not clearly linked with vascular dementia in humans (Initiated within 10 years of menopause) (0.9% vs 1.0%; RR 0.86, 95% CI 0.73-1.02).

    “No significant difference was observed for vascular dementia (0.9% vs 1.0%; RR 0.86, 95% CI 0.73-1.02; p=0.086).”

    HumansInitiated within 10 years of menopausefemales

    Early Hormone Replacement Therapy and Cognitive Outcomes in Postmenopausal Women

    AHA Scientific Sessions 2026 abstract

More on Hormone replacement therapy

Evening chronotype

no changein humans1

1 study
  1. Evening chronotype was not clearly linked with vascular dementia in humans.

    “with no significant association with Alzheimer's disease or vascular dementia (VaD).”

    HumansOverall analysis compared with morning chronotype; no statistically significant associationMean follow-up of 12.5 years

    Evening chronotype and incidence of all-cause dementia and subtypes after accounting for other sleep traits: A prospective cohort study

    Journal of Alzheimer's disease : JAD

More on Evening chronotype

Renin-angiotensin system inhibitors

no changein humans1HR 0.74

1 study
  1. Renin-angiotensin system inhibitors were not clearly linked with vascular dementia in humans (compared with calcium channel blockers) (HR 0.74, 95% CI 0.50-1.11).

    “but not vascular dementia (HR 0.74, 95% CI 0.50-1.11), compared with CCBs”

    Humanscompared with calcium channel blockers

    RAS inhibitors linked to lower dementia risk than CCBs

    Drugs & aging

More on Renin-angiotensin system inhibitors

Statins

no changein humans1HR 1.047

1 study
  1. Statins were not clearly linked with vascular dementia in humans (stroke survivors) (HR 1.047, 95% CI 0.996-1.100).

    “There was no significant difference for vascular dementia (HR 1.047, 95% CI 0.996-1.100; P = 0.072).”

    Humansstroke survivors5 years

    Neurocognitive outcomes and survival with high- vs low-intensity statins in stroke survivors: A propensity score-matched cohort (2010-2025)

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

More on Statins

Multidomain strategies

downin humans1

1 study
  1. Multidomain strategies prevent vascular dementia in humans.

    “Multidomain strategies showed greater efficacy in preventing vascular dementia”

    Review

    Vascular dementia: prevention strategies based on cardiovascular risk control – an evidence-based approach

    Journal of Medical and Biosciences Research.

More on Multidomain strategies

Chronic pain

no changein humans1

1 study
  1. Chronic pain showed no clear effect on vascular dementia in humans.

    “Chronic pain increased the risk of Alzheimer's disease and non-vascular dementia, but not vascular dementia.”

    Review

    Chronic Pain and the Risk of Dementia: A Systematic Review and Meta-Analysis

    Current pain and headache reports

More on Chronic pain

Lipoprotein

no changein humans1HR 1.05

1 study
  1. Lipoprotein was not clearly linked with vascular dementia in humans (elevated vs normal Lp(a), propensity score-matched cohort) (HR 1.05, 95% CI 0.86-1.27).

    “Alzheimer's disease (HR 1.04, 95% CI 0.85-1.27), vascular dementia (HR 1.05, 95% CI 0.86-1.27), or frontotemporal dementia (HR 0.94, 95% CI 0.48-1.83)”

    Humanselevated vs normal Lp(a), propensity score-matched cohort≥50 mg/dLup to 10 yearsn = 54,841

    Lipoprotein(a) and risk of dementia: A propensity score-matched real-world analysis from a global federated research network

    European journal of internal medicine

More on Lipoprotein

SGLT2 inhibitors

no changein humans1

1 study
  1. SGLT2 inhibitors were not clearly linked with vascular dementia in humans (compared with GLP-1 receptor agonist users).

    “No significant differences were observed for vascular dementia, mortality, or MACE.”

    Humanscompared with GLP-1 receptor agonist users

    Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulation

    GeroScience

More on SGLT2 inhibitors

All 31

Effects

9

Naples prognostic score

no changein humans1

1 study
  1. Vascular dementia was not clearly linked with Naples prognostic score in humans (mean 3.11 vs. 3.03, p = 0.432).

    “In the clinical cohort, NPS levels were similarly elevated in patients with Alzheimer's disease (AD) and vascular dementia (VaD) (mean 3.11 vs. 3.03, p = 0.432)”

    Humansn = 189

    Association between the Naples Prognostic Score and cognitive function in older adults: validation in Alzheimer's disease and vascular dementia

    Frontiers in nutrition

More on Naples prognostic score

Mortality

upin humans1

1 study
  1. Vascular dementia is linked with higher mortality in humans (coexisting cerebrovascular disease and vascular dementia) (9.38 to 40.28 per 100,000 (AAPC: 8.30, p < 0.05)).

    “The overall AAMR increased markedly from 9.38 to 40.28 per 100,000 population (AAPC: 8.30; p < 0.05).”

    Humanscoexisting cerebrovascular disease and vascular dementia2005-2023n = 200,450

    Demographic and regional disparities in mortality among older adults with coexisting cerebrovascular disease and vascular dementia in the United States, 2005-2023: A CDC WONDER analysis

    Archives of Gerontology and Geriatrics Plus

Sleep duration

downin humans1

1 study
  1. Vascular dementia is linked with lower sleep duration in humans (p < 0.05).

    “Instrumental variables of VaD and Lewy body dementia were associated with shorter sleep durations ( p < 0.05).”

    Humans

    Sleep characteristics and dementia: a multivariate Mendelian randomization study

    AAIC 2025 abstract

Serum and urine biomarkers

no changein humans1

1 study
  1. Vascular dementia was not clearly linked with serum and urine biomarkers in humans (reverse Mendelian randomization).

    “reverse Mendelian randomization indicates that VD does not causally influence the levels of the 35 examined serum and urine biomarkers.”

    Humansreverse Mendelian randomization

    Associations of 35 Serum and Urine Biomarkers With Vascular Dementia-A Mendelian Randomization Study

    Brain and behavior

More on Serum and urine biomarkers

LNPEP

upin humans1

1 study
  1. Vascular dementia is linked with higher LNPEP in humans (pure vascular dementia).

    “LNPEP gene expression was specifically elevated in VaD.”

    Humanspure vascular dementiafrontal cortexn = 42

    Altered Gene Expression Within the Renin-Angiotensin System in Normal Aging and Dementia

    The journals of gerontology. Series A, Biological sciences and medical sciences

More on LNPEP

Zonulin

no changein humans1

1 study
  1. Vascular dementia was not clearly linked with zonulin in humans (VAD vs controls).

    “Compared with controls, serum zonulin increased in LOAD, MIXED dementia, and aMCI but not in VAD”

    HumansVAD vs controls

    Serum zonulin levels are increased in Alzheimer's disease but not in vascular dementia

    Aging clinical and experimental research

More on Zonulin

HDL cholesterol

downin humans1OR 0.997

1 study
  1. Vascular dementia is linked with lower HDL cholesterol in humans (reverse MR analysis) (OR 0.997 (95% CI 0.994–0.999), p = 0.022).

    “suggestive evidence for a causal effect of genetically predicted VaD on HDL-C via reverse MR analysis”

    Humansreverse MR analysis

    Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study

    Nutrients

More on HDL cholesterol

Balance and lower-limb function

downin humans1

1 study
  1. Vascular dementia is linked with worse balance and lower-limb function in humans (vascular dementia and Lewy body dementia compared with Alzheimer's disease).

    “participants with VaD and LBD had lower odds of being able to perform FTSS and OLS than participants with AD”

    Humansvascular dementia and Lewy body dementia compared with Alzheimer's disease

    Physical performance across the cognitive spectrum and between dementia subtypes in a population-based sample of older adults: The HUNT study

    Archives of gerontology and geriatrics

Amyloid-beta 42

upin humans1+50% that in ad, and twice that in age-matched controls

1 study
  1. Vascular dementia is linked with higher amyloid-beta 42 in humans (vascular dementia vs AD and controls) (approximately 50% of that in AD, and twice that in age-matched controls).

    “mean amount of total Abeta(42) recovered from VaD samples was approximately 50% of that in AD, and twice that in the age-matched controls”

    Humansvascular dementia vs AD and controlstemporal and frontal cortices

    Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia

    Neuropathology and applied neurobiology

More on Amyloid-beta 42

Upstream

34

LDL-C

no changein humans1HR 0.96

1 study
  1. LDL-C was not clearly linked with vascular dementia in humans (Established ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dL) (HR 0.96, 95% CI 0.92-1.00; p=0.60).

    “No significant increase was observed for vascular dementia (HR 0.96, 95% CI 0.92-1.00, p=0.60).”

    HumansEstablished ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dLMedian approximately 3.1 years33.6% womens

    Very low “bad” cholesterol not linked to added cognitive risk

    AHA Scientific Sessions 2026 abstract

More on LDL-C

Subjective cognitive decline

no changein humans1

1 study
  1. Subjective cognitive decline showed no clear effect on vascular dementia in humans.

    “no significant association between SCD and risk of vascular dementia was observed.”

    Review

    Measurement of subjective cognitive decline and prediction of longitudinal clinical outcomes in older adults: a systematic review

    Journal of clinical and experimental neuropsychology

More on Subjective cognitive decline

White matter hyperintensities

mediatesin humans1OR 1.1

1 study
  1. White matter hyperintensities are linked with vascular dementia in humans (Indirect OR 1.10; descriptive mediated proportion 0.31).

    “Both had an indirect path through WMH (indirect odds ratios 1.10 and 1.05).”

    HumansIndirect effect of genetically predicted diastolic blood pressure through WMH; APOE-excluded two-step Mendelian randomization

    White matter hyperintensities partly mediate genetically predicted blood pressure effects on vascular dementia

    Research SquarePreprint

More on White matter hyperintensities

Handgrip strength

downin humans1OR 0.16

1 study
  1. Handgrip strength is linked with less vascular dementia in humans (genetically proxied, accounting for lean mass in Mendelian randomization) (OR = 0.16, 95% CI 0.04-0.64, p = 0.009).

    “grip strength showed an independent protective effect on VaD after accounting for lean mass (OR = 0.16, 95% CI 0.04-0.64, p = 0.009)”

    Humansgenetically proxied, accounting for lean mass in Mendelian randomization

    Muscle quality and blood markers linked to dementia after stroke

    Frontiers in aging neuroscience

PAM activity

no changein humans1

1 study
  1. PAM activity was not clearly linked with vascular dementia in humans.

    “Reduced PAM-AMA and lower bio-ADM levels were associated with increased risk of incident AD, but not VD.”

    Humansmean follow-up of 4.75 ± 1.3 yearsn = 4,543

    Reduced peptide amidation links to higher Alzheimer's risk

    Alzheimer's research & therapy

More on PAM activity

Sex

no changein humans1

1 study
  1. Sex showed no clear effect on vascular dementia in humans (pooled RRR: 1.003, 95% CI: 0.954-1.054).

    “vascular dementia (e.g., PM2.5: n-= 3, pooled RRR: 1.003, 95% CI: 0.954-1.054)”

    Review

    Does reported sex modify the association between ambient air pollution exposure and Alzheimer's disease and related dementias? A systematic review and meta-analysis

    Environmental pollution (Barking, Essex : 1987)

SPARCL1

downin silico1

1 study
  1. SPARCL1 protects against vascular dementia in silico.

    “SPARCL1 was identified as a key convergent candidate, demonstrating significant downregulation in aged endothelium and a consistent protective effect in MR analysis.”

    In silico

    Blood protein linked to lower vascular dementia risk

    Experimental gerontology

More on SPARCL1

Diabetic retinopathy

no changein humans1

1 study
  1. Diabetic retinopathy showed no clear effect on vascular dementia in humans (observational studies).

    “No significant association with vascular dementia was found.”

    Reviewobservational studies

    Diabetic retinopathy and dementia risk: A systematic review and meta-analysis

    Experimental gerontology

More on Diabetic retinopathy

Chronic obstructive pulmonary disease

no changein humans1

1 study
  1. Chronic obstructive pulmonary disease was not clearly linked with vascular dementia in patients with CKD stages 3-5.

    “No significant association was observed for vascular dementia alone or mild cognitive impairment alone.”

    Humansin patients with CKD stages 3-55 years

    Impact of CKD and COPD co-existence on mortality, vascular dementia, and Alzheimer's dementia; a comparative cohort study

    BMC nephrology

More on Chronic obstructive pulmonary disease

Linoleic acid percentage

mediatesin humans1

1 study
  1. Linoleic acid percentage is linked with vascular dementia in humans (mediating obesity association) (>30% proportion of mediation).

    “Glucose and the percentage of linoleic acid (LA%) were primarily responsible for mediating the association between obesity and ACD/VaD, with the proportion of mediation exceeding 30%.”

    Humansmediating obesity association

    Associations between Plasma Metabolites, Dementia and Modifiable Risk Factors

    AAIC 2025 abstract

More on Linoleic acid percentage

All 34

Associations

315

SGLT2 inhibitors

downin humans7HR 0.49–0.58

7 studies
  1. SGLT2 inhibitors are associated with vascular dementia in humans (Versus pioglitazone: aHR 0.83, 95% CI 0.69–0.99).

    “SGLT2is were associated with lower risks of all-cause and vascular dementia compared with pioglitazone, DPP-4is, and sulfonylureas.”

    HumansType 2 diabetes; compared with pioglitazone, DPP-4 inhibitors, and sulfonylureas; numerical estimate is versus pioglitazoneMean follow-up of 2.9 years

    Comparative effects of SGLT2 inhibitors, pioglitazone, DPP-4 inhibitors, and sulfonylureas on dementia risk in type 2 diabetes

    The journal of prevention of Alzheimer's disease

  2. SGLT2 inhibitors are linked with a lower risk of vascular dementia in humans (exploratory secondary analysis, compared with DPP-4 inhibitor users) (HR 0.49; p = 0.005).

    “associations were observed for vascular dementia (HR, 0.49; p = 0.005) and all-cause mortality (HR, 0.76; p < 0.001)”

    Humansexploratory secondary analysis, compared with DPP-4 inhibitor usersn = 3,877

    Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study

    Drug design, development and therapy

  3. SGLT2 inhibitors are linked with a lower risk of vascular dementia in humans (compared with thiazolidinediones, in adults with type 2 diabetes on metformin) (aHR 0.29 (95% CI 0.09-0.94)).

    “SGLT2 inhibitors were associated with a lower risk of vascular dementia than TZD (0.29;0.09-0.94)”

    Humanscompared with thiazolidinediones, in adults with type 2 diabetes on metforminup to 5 years

    Effect of thiazolidinediones compared to other antidiabetic medications on incident dementia in people with type 2 diabetes: A target trial emulation study

    medRxivPreprint

  4. SGLT2 inhibitors are linked with a lower risk of vascular dementia in humans (compared with incretin mimetics in type 2 diabetes) (HR 0.49, 95% CI 0.35–0.70).

    “SGLT2i also reduced the risks of vascular dementia and Alzheimer's disease (HR 0.49, 95% CI: 0.35-0.70 vs. HR 0.68, 95% CI: 0.52-0.88, respectively).”

    Humanscompared with incretin mimetics in type 2 diabetes

    Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis

    Frontiers in endocrinology

  5. SGLT2 inhibitors are linked with a lower risk of vascular dementia in humans (compared with DPP-4 inhibitors in type 2 diabetes) (IRR 0.573 (95% CI 0.204-1.605), non-significant).

    “and vascular dementia (I2 = 0.0 %, P = 0.971; IRR = 0.573; 95 % CI: 0.204-1.605; P = 0.289)”

    Humanscompared with DPP-4 inhibitors in type 2 diabetes

    SGLT2 inhibitors versus DPP-4 inhibitors and dementia risk in type 2 diabetes: A meta-analysis of cohort studies

    Archives of gerontology and geriatrics

  6. SGLT2 inhibitors are linked with a lower risk of vascular dementia in humans (patients with type 2 diabetes; pooled from observational studies) (HR 0.58 (0.44-0.78)).

    “The use of SGLT-2 inhibitors versus non-use is associated with a decreased risk of all-cause dementia (HR [95% CI]: 0.76 [0.67-0.85]), AD (0.75 [0.61-0.92]), and VD (0.58 [0.44-0.78]).”

    Humanspatients with type 2 diabetes; pooled from observational studies

    Systematic Review and Meta-analysis of the Association of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Dementia in Patients with Type 2 Diabetes

    ADA Scientific Sessions 2025 abstract

  7. SGLT2 inhibitors lower the risk of vascular dementia in patients with T2DM (HR = 0.54; 95% CI: 0.49-0.60).

    “vascular dementia (HR = 0.54; 95% CI: 0.49-0.60) compared to DPP-4 inhibitors”

    Reviewin patients with T2DM

    Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP-4 Inhibitors: A Systematic Review and Meta-Analysis

    Endocrinology, diabetes & metabolism

More on SGLT2 inhibitors

Hypertension

upin humans6OR 2.72

6 studies
  1. Hypertension is linked with a higher risk of vascular dementia in humans (OR 2.72, 95% CI 1.66-4.45).

    “Genetically predicted hypertension was associated most clearly with vascular dementia (odds ratio 2.72, 95% confidence interval 1.66-4.45; P = 0.0001)”

    Humans

    Global, Regional and National burden of dementia attributable to metabolic dysregulation from 1990 to 2021, with projections of burden to 2050: An analysis of the global burden of disease study 2021

    Diabetes & metabolic syndrome

  2. Hypertension is associated with vascular dementia in humans (Hypertension versus non-elevated blood pressure) (aHR 1.372).

    “The associations were particularly pronounced for VaD (elevated BP: aHR 1.159; hypertension: aHR 1.372)”

    HumansHypertension versus non-elevated blood pressureMean follow-up of 8.1 years

    Dementia risk across blood pressure categories: a South Korean nationwide study

    European heart journal

  3. Hypertension is associated with vascular dementia in humans (HR 1.92, 95% CI 1.14–3.24).

    “Hypertension was associated with VaD/AD mixed (HR, 1.92 [95% CI = 1.14, 3.24]) but not AD.”

    Humansn = 2,564

    An assessment of the mediating role of hypertension in the effect of long-term air pollution exposure on dementia

    Environmental epidemiology (Philadelphia, Pa.)

  4. Hypertension is linked with a higher risk of vascular dementia in humans after controlling for factors other than stroke-related factors.

    “Hypertension was correlated with incident VaD.”

    Humansafter controlling for factors other than stroke-related factorsn = 1,285

    Predictive value of hypercholesterolemia, vegetarian diet, and hypertension for incident dementia among elderly Taiwanese individuals with low educational levels

    Therapeutic advances in chronic disease

  5. Hypertension raises the risk of vascular dementia in humans (midlife).

    “Midlife hypertension emerges as a key risk factor, especially for vascular dementia, while late-life BP effects are variable.”

    Reviewmidlife

    Epidemiological and clinical evidence on blood pressure management for the prevention of dementia: striving for a healthy 100-year life

    Hypertension research : official journal of the Japanese Society of Hypertension

  6. Hypertension raises the risk of vascular dementia in humans.

    “several vascular risk factors, such as hypertension, obesity, and diabetes have been shown to exacerbate neurovascular impairments and thus increase VaD prevalence.”

    Review

    Neurovascular Alterations in Vascular Dementia: Emphasis on Risk Factors

    Frontiers in aging neuroscience

More on Hypertension

Atrial fibrillation

upin humans6RR 1.8

6 studies
  1. Atrial fibrillation is associated with vascular dementia in humans (Compared with individuals without atrial fibrillation) (Adjusted HR 2.06, 95% CI 1.80–2.36).

    “and vascular dementia (VD; adjusted HR, 2.06; 95% CI, 1.80-2.36)”

    HumansCompared with individuals without atrial fibrillationMedian follow-up of 12.6 yearsBothsn = 433,746

    Age at Diagnosis of Atrial Fibrillation and Incident Dementia

    JAMA network open

  2. Atrial fibrillation is associated with vascular dementia in humans (HR 1.58, 95% CI 1.42-1.77).

    “AF was associated with VD (HR 1.58, 95% CI 1.42-1.77)”

    Humans

    Increased risk of dementia differs across cardiovascular diseases and types of dementia - Data from a nationwide study

    Journal of internal medicine

  3. Atrial fibrillation is linked with a higher risk of vascular dementia in humans (genetically predicted (Mendelian randomization)) (OR 1.350 (95% CI 1.076-1.695)).

    “strongly associated with vascular dementia (odds ratio, 1.350 [95% CI, 1.076-1.695]; P=0.010)”

    Humansgenetically predicted (Mendelian randomization)

    Genetic Evidence for Causal Association Between Atrial Fibrillation and Dementia: A Mendelian Randomization Study

    Journal of the American Heart Association

  4. Atrial fibrillation is associated with vascular dementia in humans.

    “AF was strongly associated with age, cardiovascular history, congestive heart failure, as well as with multiple geriatric syndromes such as vascular dementia, malnutrition, functional decline in Activities of Daily Living, mobility impairment and chronic ulcerous disease.”

    Humansn = 207

    Association between atrial fibrillation, frailty, and geriatric syndromes in the late elderly in a south Belgian outpatient and inpatient setting

    American heart journal plus : cardiology research and practice

  5. Atrial fibrillation raises the risk of vascular dementia in humans (genetically predicted).

    “identified evidence of potential causal effects between genetically predicted exposures, such as atrial fibrillation, major depressive disorder and gut microbiota, on vascular dementia risk”

    Reviewgenetically predicted

    A systematic review of risk factors for vascular dementia using Mendelian randomization: a call for methodologically robust studies to advance knowledge

    BMC neurology

  6. Atrial fibrillation is associated with vascular dementia in humans (OR/RR: 1.80, 95% CI: 1.57-2.07).

    “Similarly, a significant association was found between AF and an increased risk of VaD”

    Review

    Association between Atrial Fibrillation and Risk of Alzheimer's Disease and Vascular Dementia: A Systematic Review and Meta-analysis

    Annals of Indian Academy of Neurology

More on Atrial fibrillation

Metabolic syndrome

upin humans5HR 1.362–3.14

5 studies
  1. Metabolic syndrome is associated with vascular dementia in humans (Metabolic syndrome and no MVPA versus no metabolic syndrome and high physical activity) (HR 3.14 (1.60–6.14)).

    “for VD, 3.14 (1.60-6.14), compared with the reference group of No MetS-High PA”

    HumansMetabolic syndrome and no MVPA versus no metabolic syndrome and high physical activityNo moderate-to-vigorous physical activityMedian follow-up of 13 years

    Physical activity and metabolic syndrome in relation to incident dementia in UK biobank

    Nutrition & metabolism

  2. Metabolic syndrome is associated with vascular dementia in humans (Metabolic syndrome at baseline) (HR 1.362, 95% CI 1.195–1.551).

    “MetS at baseline significantly affected the risk of developing VaD (HR: 1.362, 95 % CI: 1.195, 1.551)”

    HumansMetabolic syndrome at baselinen = 313,179

    Inflammation mediates the association between metabolic syndrome and vascular dementia: A large prospective cohort study

    Atherosclerosis

  3. Metabolic syndrome is associated with vascular dementia in humans (Metabolic syndrome compared with the non-metabolic syndrome group in Korea) (HR 1.53, 95% CI 1.44–1.71).

    “and the risk of vascular dementia was 1.53-fold (95% CI: 1.44 1.71) greater.”

    HumansMetabolic syndrome compared with the non-metabolic syndrome group in Korea2009 through December 31, 2018

    Effect of Metabolic Syndrome on the Incidence of Dementia Based on National Insurance Data in Korea

    Metabolic syndrome and related disorders

  4. Metabolic syndrome is associated with vascular dementia in humans.

    “Overall, MetS was associated with adverse cognitive outcomes, with relatively more consistent evidence for vascular dementia”

    Review

    Metabolic Syndrome and Dementia Risk in Older Adults: A Narrative Review

    The Kaohsiung journal of medical sciences

  5. Metabolic syndrome raises the risk of vascular dementia in humans (RR = 1.33, 95%CI: 1.21-1.46).

    “VD (RR = 1.33, 95%CI: 1.21-1.46; absolute risk difference: 7 more per 1000)”

    Review

    Metabolic syndrome and risk of dementia and cognitive decline: a systematic review and meta-analysis of prospective cohort studies from 6,753,197 participants

    GeroScience

More on Metabolic syndrome

Systolic blood pressure

upin humans4HR 1.95

4 studies
  1. Systolic blood pressure is associated with vascular dementia in humans (HR 1.95 (95% CI 1.03–3.68)).

    “a higher risk of vascular dementia [HR 1.95 (95% confidence interval: 1.03-3.68)] compared to the reference (120 to <140 mmHg) group.”

    HumansJapanese-American men without baseline dementia; systolic blood pressure ≥160 versus 120 to <140 mmHgUp to 20 yearsmalesn = 2,649

    High blood pressure linked to contrasting dementia risks in men

    Journal of Alzheimer's disease : JAD

  2. Systolic blood pressure is associated with vascular dementia in humans (Genetically predicted blood pressure; European ancestry) (OR 1.12).

    “Diastolic and systolic BP associated with VaD (odds ratios 1.36 and 1.12).”

    HumansGenetically predicted blood pressure; European ancestry

    White matter hyperintensities partly mediate genetically predicted blood pressure effects on vascular dementia

    Research SquarePreprint

  3. Systolic blood pressure is linked with a higher risk of vascular dementia in humans (genetically proxied) (OR 1.56 (95% CI 1.25-1.93), HR 1.58 (95% CI 1.28-1.97)).

    “higher SBP was associated with increased risk of VaD (OR=1.56, [95% CI:1.25;1.93]; HR=1.58, [95% CI:1.28;1.97])”

    Humansgenetically proxied

    Hypertension and Dementia: A Mendelian Randomisation Study Assessing Potential Causal Relationships with All-Cause Dementia, Alzheimer’s Disease and Vascular Dementia in the UK Biobank

    medRxivPreprint

  4. Vascular dementia is associated with systolic blood pressure in humans.

    “the VaD group had a higher SBP than the AD group at HUNT2 and 3.”

    Humans

    Blood pressure trajectories over 35 years and dementia risk: A retrospective study: The HUNT study

    Frontiers in aging neuroscience

More on Systolic blood pressure

GLP-1 receptor agonists

downin humans4HR 0.56–0.67

4 studies
  1. GLP-1 receptor agonists are linked with a lower risk of vascular dementia in humans (compared with DPP-4 inhibitor initiation, in COVID-19 survivors with type 2 diabetes) (HR 0.67 (95% CI 0.52–0.85)).

    “vascular dementia (HR, 0.67; 95% CI, 0.52-0.85)”

    Humanscompared with DPP-4 inhibitor initiation, in COVID-19 survivors with type 2 diabetesup to 6 yearsn = 25,263

    GLP-1 agonists linked to lower dementia risk after COVID-19

    Drug design, development and therapy

  2. GLP-1 receptor agonists are linked with a lower risk of vascular dementia in humans (HR 0.56 (95% CI 0.32–0.99)).

    “Compared to non-use, GLP-RA use was associated with a lower risk of stroke (HR: 0.84 [0.76-0.93]), VD (0.56 [0.32-0.99]), and ADRD (0.74 [0.63-0.86]).”

    Humansin adults with obesity, target trial emulation with time-dependent propensity score matchingn = 61,880

    Glucagon-Like Peptide 1 Receptor Agonists Lower the Risk of Stroke and Vascular Dementia among Individuals with Obesity

    ADA Scientific Sessions 2026 abstract

  3. GLP-1 receptor agonists are linked with a lower risk of vascular dementia in humans (compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes) (HR 0.62, 95% CI 0.55–0.70).

    “Alzheimer's disease (HR, 0.62; 95% CI, 0.56-0.70), and vascular dementia (HR, 0.62; 95% CI, 0.55-0.70)”

    Humanscompared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetesn = 82,689

    Glucagon-Like Peptide-1 Receptor Agonists and Dementia Risk Reduction in Older Adults With Type 2 Diabetes: A Retrospective Cohort Study

    Journal of the American Medical Directors Association

  4. GLP-1 receptor agonists are linked with a lower risk of vascular dementia in obese patients (RR 0.438, 95% CI 0.327-0.588).

    “vascular dementia (RR = 0.438, 95 %CI = 0.327-0.588)”

    Humansin obese patients

    Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study

    International immunopharmacology

More on GLP-1 receptor agonists

Type 2 diabetes

upin humans4HR 1.62–5.82

4 studies
  1. Type 2 diabetes is linked with a higher risk of vascular dementia in humans (incident type 2 diabetes) (AHR 1.57, 95% CI 1.20-2.07).

    “and VaD (1.57, 1.20-2.07)”

    Humansincident type 2 diabetesmedian 3.67 yearsn = 42,514

    Age at type 2 diabetes onset and risk of dementia: The modifying role of genetic susceptibility and mitochondrial function

    The journal of nutrition, health & aging

  2. Type 2 diabetes is linked with a higher risk of vascular dementia in humans (T2D) (HR:1.62).

    “and vascular dementia (HR:1.62).”

    HumansT2Dmedian 6.19 yearsn = 104,911

    Incidence and synergistic Association of Type 2 diabetes and apolipoprotein E epsilon 4 with dementia risk in the Kunshan aging research with E-health cohort study

    Preventive medicine

  3. Type 2 diabetes is linked with a higher risk of vascular dementia in humans (newly diagnosed T2DM) (HR 5.82 (95% CI 3.84-8.81)).

    “and 5.82 (3.84-8.81) for VD”

    Humansnewly diagnosed T2DM

    Association between Age at Diagnosis of Type 2 Diabetes and Subsequent Risk of Dementia and Its Major Subtypes

    Journal of clinical medicine

  4. Type 2 diabetes is linked with a higher risk of vascular dementia in humans (RR 2.3, 95% CI 1.1-5.0).

    “vascular dementia (VsD; 2.3 [1.1-5.0])”

    Humansmalesn = 2,574

    Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study

    Diabetes

More on Type 2 diabetes

Smoking

upin humans3RR 1.52

3 studies
  1. Smoking predicts vascular dementia in humans (Patients with acute ischemic stroke following intravenous thrombolytic therapy).

    “Multivariate logistic regression identified smoking history, coronary artery disease, hyperglycemia, elevated Systemic Immune-Inflammation Index, increased platelet-to-lymphocyte ratio, lipoprotein, D-dimer, large-vessel stenosis, and strategic infarct location as independent predictors.”

    HumansPatients with acute ischemic stroke following intravenous thrombolytic therapyn = 219

    Analysis of risk factors for vascular dementia following thrombolytic therapy in patients with acute ischemic stroke

    Medicine

  2. Smoking is associated with vascular dementia in humans (Current smoking at baseline).

    “Current smokers had an increased risk for vascular dementia but not for Alzheimer's dementia.”

    HumansCurrent smoking at baselineTwo decades

    Smoking is associated with increased risk for dementia: the HUNT study, Norway

    BMC public health

  3. Smoking is associated with vascular dementia in humans (RR 1.52, 95% CI 1.20–1.93).

    “vascular dementia (1.52 [1.20–1.93]; k = 9)”

    Reviewcurrent smoking

    Smoking and dementia risk: an updated systematic review and meta-analysis of 61 prospective cohort studies and implications for tobacco control

    EClinicalMedicine

More on Smoking

Age-related macular degeneration

downin humans2no changein humans1OR 0.93

3 studies
  1. Age-related macular degeneration is associated with vascular dementia in humans (0.65% vs. 0.57%, p = 0.08 at 10 years).

    “vascular dementia (0.60% vs. 0.54%, p = 0.15; 0.65% vs. 0.57%, p = 0.08) were similar between cohorts.”

    Humans10 years

    Association of Age-Related Macular Degeneration and Dementia: A Health Registry Database Study

    Journal of Clinical & Translational Ophthalmology

  2. Vascular dementia is linked with a lower risk of age-related macular degeneration in humans (Genetically predicted vascular dementia; European ancestry) (OR 0.93, 95% CI 0.87–0.99).

    “Vascular dementia showed negative associations with age-related macular degeneration (odds ratio = 0.93, 95% confidence interval: 0.87-0.99)”

    HumansGenetically predicted vascular dementia; European ancestry

    Causal associations between cognitive impairments and retinal diseases: A two-sample Mendelian randomization study

    The Journal of international medical research

  3. Age-related macular degeneration is linked with a lower risk of vascular dementia in humans (United States cohort) (HR = 0.73 and 0.79; P < 0.0001 and 0.0003).

    “Vascular dementia showed no global association but was reduced in the United States at 5 and 7 years (HR = 0.73 and 0.79; P < 0.0001 and 0.0003).”

    HumansUnited States cohort5 and 7 years

    Longitudinal Assessment of Age-Related Macular Degeneration and Risk of Dementia Using Clinical Setting Data

    Ophthalmology science

More on Age-related macular degeneration

Retinal vascular occlusion

upin humans3HR 1.15–1.3

3 studies
  1. Retinal vascular occlusion is linked with a higher risk of vascular dementia in humans.

    “Participants with retinal vascular occlusions, RVOs, or BRVOs demonstrated higher risk of all-cause dementia and VaD.”

    Humansaverage of 6.29 yearsn = 21,367

    The association between retinal vascular occlusions and dementia using TriNetX

    Journal of Alzheimer's disease : JAD

  2. Retinal vascular occlusion is linked with a higher risk of vascular dementia in humans (HR 1.30, 95% CI 1.16-1.47).

    “1.30 (95% CI, 1.16-1.47) for vascular dementia”

    Humans5 years

    Risk of dementia following retinal vascular occlusions: A propensity-score matched cohort study using a global federated database

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

  3. Retinal vascular occlusion is associated with vascular dementia in humans (HR 1.15, 95% CI 1.04–1.28).

    “the pooled hazard ratio for vascular dementia showed a statistically significant increased risk in patients with RVO at 1.15”

    Review

    Does retinal vascular occlusion increase the risk of dementia? A pioneering systematic review and meta-analysis

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

More on Retinal vascular occlusion

All 315

Trial sponsors

Funding

28 grants since 2016

National Institute on Aging$19.3MNational Institute of Neurological Disorders and Stroke$6.7MAmerican Heart Association$1.4M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human cohorts link vascular dementia with hypertension, metabolic syndrome, frailty, and higher biological age. Physical activity is associated with lower risk among myocardial infarction survivors. Weekend recovery sleep shows opposite associations depending on weekday sleep duration: lower risk with less-than-optimal weekday sleep and higher risk with prolonged weekday sleep.

  2. Summary rewritten as its findings changed.

    As it read before

    Human cohorts link hypertension, type 2 diabetes, frailty, and higher biological age with greater vascular dementia risk. Genetic analyses link higher LDL cholesterol with greater risk. Weekend recovery sleep is linked with lower risk when weekday sleep is shorter than optimal, but higher risk when weekday sleep exceeds optimal duration.

  3. Summary rewritten as its findings changed.

    As it read before

    Human cohorts link vascular dementia with hypertension, type 2 diabetes, frailty and higher biological age. Remaining active during the first year after myocardial infarction is linked with lower risk. Weekend recovery sleep is linked with lower risk when weekday sleep is shorter than optimal, but higher risk when weekday sleep is longer than optimal.

  4. Summary rewritten as its findings changed.

    As it read before

    Human cohorts link biological age, brain age gap and frailty with higher vascular dementia risk, alongside hypertension and type 2 diabetes. A human study links weekend recovery sleep with lower risk when weekday sleep is shorter than optimal, but higher risk when weekday sleep exceeds the optimal duration.

  5. Summary rewritten as its findings changed.

    As it read before

    Frailty, greater biological age, higher blood pressure, and type 2 diabetes are linked with higher vascular dementia risk in human cohorts. Genetic analyses link higher LDL and total cholesterol with higher risk in people of European ancestry. Weekend recovery sleep is linked with lower risk when weekday sleep is shorter than optimal, but higher risk when it is longer.

Latest

Dec 2025: 68Jan 2026: 28Feb 2026: 31Mar 2026: 33Apr 2026: 31May 2026: 30Jun 2026: 37Jul 2026: 37Aug 2026: 31Sep 2026: 28Oct 2026: 34Nov 2026: 20408 papers in 12 months
Acta Neurologica Belgica

Diabetes drugs linked to lower death risk in vascular dementia

One-year mortality was 8.7% among people taking the drugs, compared with 15.9% among matched non-users.One-year mortality was 8.7% among people taking the drugs, compared with 15.9% among matched non-users.

Cohort studyVascular dementia
AHA Scientific Sessions 2026 Abstract

Very low “bad” cholesterol not linked to added cognitive risk

Cognitive impairment risk was similar—a hazard ratio of 1.00—at “bad” cholesterol below 30 mg/dL versus 30–55 mg/dL in adults with artery disease.Cognitive impairment risk was similar—a hazard ratio of 1.00—at “bad” cholesterol below 30 mg/dL versus 30–55 mg/dL in adults with artery disease.

Cohort studyPopulations
AHA Scientific Sessions 2026 Abstract

Stress-related and sleep disorders linked to dementia risk

During follow-up from 2018 through 2023, dementia occurred in 6.8% of adults with both disorder types versus 2.3% with neither.During follow-up from 2018 through 2023, dementia occurred in 6.8% of adults with both disorder types versus 2.3% with neither.

Cohort · 178,655 peopleIncident dementia

See all 1,220 papers on vascular dementia